Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study

Diabetes Research and Clinical Practice

Volumn 108, Issue 3, 2015, Pages 432-440

  Balkau, Beverley ^a,b   Calvi Gries, Françoise ^c   Freemantle, Nick ^d   Vincent, Maya ^e   Pilorget, Valerie ^e   Home, Philip D ^f  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c AtlanStat ^*  (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e SANOFI   (France)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Glycaemic control; Insulin therapy; Observational; Predictors; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; DISEASE DURATION; DRUG DOSE; DRUG DOSE INCREASE; DRUG USE; FAMILY HISTORY; FEMALE; FOLLOW UP; GENDER; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PREMATURE CARDIOVASCULAR DISEASE; PROSPECTIVE STUDY; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT GAIN; BLOOD; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TIME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84930182510     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.02.034     Document Type: Article

References (23)

1. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853.
2. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
3. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
4. Hayes R.P., Fitzgerald J.T., Jacober S.J. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract 2008, 62(6):860-868.
5. Kunt T., Snoek F.J. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 2009, 164:6-10.
6. Peyrot M., Rubin R.R., Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes 2010, 4(Suppl 1):S11-S18.
7. Home P.D., Shen C., Hasan M.I., Latif Z.A., Chen J.W., Gonzalez G.G. Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs. Diabetes Care 2014, 37(5):1237-1245.
8. Freemantle N., Balkau B., Danchin N., Wang E., Marre M., Vespasiani G., et al. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes Obes Metab 2012, 14(10):901-909.
9. Home P.D., Dain M.-P., Freemantle N., Kawamori R., Pfohl M., Pilorget V., et al. Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetologia 2013, 56(Suppl 1):S410.
10. Miller M.E., Bonds D.E., Gerstein H.C., Seaquist E.R., Bergenstal R.M., Calles-Escandon J., ACCORD Investigators, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010, 340:b5444.
11. Holman R.R., Thorne K.I., Farmer A.J., Davies M.J., Keenan J.F., Paul S., 4-T Study Group, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357(17):1716-1730.
12. Holman R.R., Farmer A.J., Davies M.J., Levy J.C., Darbyshire J.L., Keenan J.F., 4-T Study Group, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009, 361(128):1736-1747.
13. Riddle M.C., Vlajnic A., Zhou R., Rosenstock J. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. Diabetes Obes Metab 2013, 15(9):819-825.
14. Curtis B., Lage M.J. Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. J Med Econ 2014, 17(1):21-31.
15. Nichols G.A., Kimes T.M., Harp J.B., Kou T.D., Brodovicz K.G. Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes. Diabetes Care 2012, 35(3):495-497.
16. Wu N., Aagren M., Boulanger L., Friedman M., Wilkey K. Assessing achievement and maintenance of glycemic control by patients initiating basal insulin. Curr Med Res Opin 2012, 28(10):1647-1656.
17. Khunti K., Caputo S., Damci T., Dzida G.J., Ji Q., Kaiser M., SOLVE Study Group, et al. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obes Metab 2012, 14(12):1129-1136.
18. Valensi P., Shaban J., Benroubi M., Kawamori R., Borzì V., Shah S., IMPROVE Study Expert Panel, et al. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study. Curr Med Res Opin 2013, 29(6):601-609.
19. Freemantle N., Balkau B., Home P.D. A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes. Diabetes Obes Metab 2013, 15(12):1120-1127.
20. Hanefeld M., Bramlage P. Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. Curr Diab Rep 2013, 13(3):342-349.
21. Owens D.R. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther 2013, 15(9):776-785.
22. Goodall G., Sarpong E.M., Hayes C., Valentine W.J. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord 2009, 9:19.
23. Raz I., Riddle M.C., Rosenstock J., Buse J.B., Inzucchi S.E., Home P.D., et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 2013, 36(6):1779-1788.